MSFT   213.35 (+0.24%)
AMZN   3,127.73 (+1.51%)
BABA   260.04 (+0.92%)
GE   6.63 (-3.50%)
TSLA   1,374.61 (+0.64%)
AMD   56.28 (+5.31%)
T   29.59 (-2.86%)
DIS   116.24 (-0.36%)
BAC   22.45 (-2.86%)
BA   173.77 (-3.50%)
MSFT   213.35 (+0.24%)
AMZN   3,127.73 (+1.51%)
BABA   260.04 (+0.92%)
GE   6.63 (-3.50%)
TSLA   1,374.61 (+0.64%)
AMD   56.28 (+5.31%)
T   29.59 (-2.86%)
DIS   116.24 (-0.36%)
BAC   22.45 (-2.86%)
BA   173.77 (-3.50%)
MSFT   213.35 (+0.24%)
AMZN   3,127.73 (+1.51%)
BABA   260.04 (+0.92%)
GE   6.63 (-3.50%)
TSLA   1,374.61 (+0.64%)
AMD   56.28 (+5.31%)
T   29.59 (-2.86%)
DIS   116.24 (-0.36%)
BAC   22.45 (-2.86%)
BA   173.77 (-3.50%)
MSFT   213.35 (+0.24%)
AMZN   3,127.73 (+1.51%)
BABA   260.04 (+0.92%)
GE   6.63 (-3.50%)
TSLA   1,374.61 (+0.64%)
AMD   56.28 (+5.31%)
T   29.59 (-2.86%)
DIS   116.24 (-0.36%)
BAC   22.45 (-2.86%)
BA   173.77 (-3.50%)
Log in

NASDAQ:AMGNAmgen Stock Price, Forecast & News

$251.70
+0.11 (+0.04 %)
(As of 07/9/2020 02:12 PM ET)
Add
Compare
Today's Range
$248.84
Now: $251.70▼
$253.83
50-Day Range
$217.90
MA: $231.72▼
$258.24
52-Week Range
$173.12
Now: $251.70▼
$264.97
Volume807,699 shs
Average Volume2.86 million shs
Market Capitalization$148.06 billion
P/E Ratio19.73
Dividend Yield2.53%
Beta0.94
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, and neuroscience. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, a pegylated protein to treat cancer patients; Prolia to treat postmenopausal women with osteoporosis; Aranesp to treat anemia; Xgeva for skeletal-related events prevention; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; and EPOGEN to treat a lower-than-normal number of red blood cells. It also markets other products in various markets, including Kyprolis, Nplate, Vectibix, Repatha, NEUPOGEN, Parsabiv, Blincyto, Aimovig, Imlygic, Corlanor, Kanjintitm, and Amgevitatm. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaborative agreements with Novartis; UCB; Bayer HealthCare Pharmaceuticals Inc.; and DaVita Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Read More
Amgen logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.3Community Rank: 3.0Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.3 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

2.17 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:AMGN
Previous Symbol
CUSIP03116210
CIK318154
Webwww.amgen.com
Phone805-447-1000

Debt

Debt-to-Equity Ratio3.16
Current Ratio1.59
Quick Ratio1.28

Price-To-Earnings

Trailing P/E Ratio19.73
Forward P/E Ratio16.18
P/E Growth2.16

Sales & Book Value

Annual Sales$23.36 billion
Price / Sales6.34
Cash Flow$18.80 per share
Price / Cash Flow13.39
Book Value$16.28 per share
Price / Book15.46

Profitability

EPS (Most Recent Fiscal Year)$14.82
Net Income$7.84 billion
Net Margins32.03%
Return on Equity90.75%
Return on Assets15.44%

Miscellaneous

Employees23,400
Outstanding Shares588,250,000
Market Cap$148.06 billion
Next Earnings Date7/28/2020 (Confirmed)
OptionableOptionable
NASDAQ:AMGN Rates by TradingView

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Amgen (NASDAQ:AMGN) Frequently Asked Questions

How has Amgen's stock been impacted by COVID-19 (Coronavirus)?

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMGN stock has increased by 26.5% and is now trading at $251.36. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amgen?

28 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 1 sell rating, 11 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amgen.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for Amgen.

How can I listen to Amgen's earnings call?

Amgen will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Amgen's earnings last quarter?

Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Thursday, April, 30th. The medical research company reported $4.17 EPS for the quarter, beating the consensus estimate of $3.70 by $0.47. The medical research company earned $6.16 billion during the quarter, compared to analyst estimates of $6.01 billion. Amgen had a return on equity of 90.75% and a net margin of 32.03%. The firm's revenue for the quarter was up 10.9% on a year-over-year basis. During the same period in the previous year, the business earned $3.56 earnings per share. View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 4th. Stockholders of record on Monday, May 18th will be given a dividend of $1.60 per share on Monday, June 8th. This represents a $6.40 dividend on an annualized basis and a yield of 2.55%. The ex-dividend date is Friday, May 15th. View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY20 earnings guidance on Thursday, April, 30th. The company provided EPS guidance of $14.85-15.60 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $15.34. The company issued revenue guidance of $25.0-25.6 billion, compared to the consensus revenue estimate of $25.21 billion.

What price target have analysts set for AMGN?

28 analysts have issued twelve-month price targets for Amgen's shares. Their forecasts range from $185.00 to $291.00. On average, they expect Amgen's share price to reach $246.08 in the next year. This suggests that the stock has a possible downside of 2.1%. View analysts' price targets for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. According to Zacks Investment Research, "In 2020, while Amgen’s growth products like Prolia, Evenity, Repatha, Aimovig, Otezla and biosimilars will drive sales, increasing competition for its legacy products will continue to hurt the same. Amgen boasts a strong biosimilars portfolio. It is also progressing with its pipeline while regularly pursuing “external opportunities” such as the acquisition of Otezla and the recently acquired stake in China's BeiGene. Amgen also expects several important clinical data readouts from its innovative pipeline in 2020. However, pricing and competitive pressure are concerns. Amgen’s shares have outperformed the industry in the past one year. Estimates have gone down ahead of Q1 results due to uncertainty about the impact of the coronavirus pandemic on results. Amgen has a positive record of earnings surprise in recent quarters." (4/15/2020)
  • 2. William Blair analysts commented, "We ultimately view the deal as positive for Amgen and a good fit for management’s strategy given the low-risk nature of the deal and immediate accretion." (8/30/2019)
  • 3. Evercore ISI analysts commented, "We used a discount rate which is a function of cost of equity and cost of debt. Terminal growth rate estimates were used to derive future cash flows." (8/11/2019)

Has Amgen been receiving favorable news coverage?

News coverage about AMGN stock has trended negative on Thursday, according to InfoTrie. The research firm scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news about Amgen.

Who are some of Amgen's key competitors?

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), Walt Disney (DIS), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD) and AbbVie (ABBV).

Who are Amgen's key executives?

Amgen's management team includes the following people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 56)
  • Mr. David W. Meline, Exec. VP & CFO (Age 62)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 58)
  • Dr. David M. Reese M.D., Exec. VP of R&D (Age 56)
  • Mr. Murdo Gordon, Exec. VP of Global Commercial Operations (Age 52)

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by many different institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.09%), Cullinan Associates Inc. (0.03%), State of Alaska Department of Revenue (0.02%), DNB Asset Management AS (0.02%), Cardinal Capital Management Inc. (0.01%) and Oak Asset Management LLC (0.01%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, Ronald D Sugar, Sean E Harper and Tyler Jacks. View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc., Thomasville National Bank, Municipal Employees Retirement System of Michigan, West Branch Capital LLC, Nelson Van Denburg & Campbell Wealth Management Group LLC, OmniStar Financial Group Inc., Legacy Private Trust Co., and M&R Capital Management Inc.. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, R Sanders Williams, and Ronald D Sugar. View insider buying and selling activity for Amgen.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Cullinan Associates Inc., O Keefe Stevens Advisory Inc., DNB Asset Management AS, State of Alaska Department of Revenue, Renaissance Investment Group LLC, American National Bank, Wiley BROS. Aintree Capital LLC, and HBW Advisory Services LLC. View insider buying and selling activity for Amgen.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $251.36.

How big of a company is Amgen?

Amgen has a market capitalization of $147.86 billion and generates $23.36 billion in revenue each year. The medical research company earns $7.84 billion in net income (profit) each year or $14.82 on an earnings per share basis. Amgen employs 23,400 workers across the globe.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.